Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen - Wikidata - awgldk - TriplyDB

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

http://www.wikidata.org/entity/Q27026180

about

Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.Tamoxifen metabolite endoxifen interferes with the polyamine pathway in breast cancer.

P2860

Q35768721-7E6BDE4D-CBDD-4072-A6A4-236D02A48298 Q38649909-AC2172CD-3360-4F76-9CE7-35C6DE3FE969 Q39580768-80C48663-125D-44B8-B46E-C417D6B57D12

P2860

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

http://www.wikidata.org/entity/Q27026180

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@ast

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@en

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@nl

type

label

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@ast

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@en

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@nl

prefLabel

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@ast

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@en

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@nl

P1433

Q27026180-D8425631-B60E-43A5-B3F4-35EBBE777F2C

P1476

Q27026180-475A6F97-BCD8-4D27-8228-7623DD905A72

P2093

Q27026180-49C72EC2-7D1B-421C-840E-CD229C494208

Q27026180-B1FDED61-09C8-4F52-A2FF-F869C70BA928

P2860

Q27026180-0353D809-2337-4C74-B930-D808A0F1C09A

Q27026180-05107622-2195-4CD7-82E4-47FFBFD20146

Q27026180-06060FC7-9703-4942-AFAC-E758639FCD46

Q27026180-09BE18C8-97B6-40C0-90CA-60A4DB6AA915

Q27026180-13C6809B-F116-4EA7-B36A-8AD0E75E08E1

Q27026180-1D8A6791-2C7A-4D17-B3E9-3689A0F66643

Q27026180-238851E7-F25E-4FC4-97DF-27811D657BC4

Q27026180-29B6999E-8D57-4DBD-A9E8-2268CE10ECE0

Q27026180-2C1A887D-62FE-4207-8C03-B84953172F3D

Q27026180-31A6B001-382C-4BB6-A060-B3700105E364

P304

Q27026180-AD52A728-40AA-48D8-BB5C-723A7153EFEF

P31

Q27026180-F54E4A01-18E7-4D09-BC87-C6516B4051DE

P356

Q27026180-9D86D1C9-2B91-41B7-A681-8DD2315C3C3A

P407

Q27026180-92A7BE95-4573-487D-8EB0-9064C9E9D37C

P433

Q27026180-A45C210B-E596-4FBE-8A45-E84B78E35412

P478

Q27026180-95D090CA-65DE-40C0-8F0B-375B0D5B03A1

P50

Q27026180-9E1CBD8E-ED7D-41B8-8942-4CBC40A769C8

P577

Q27026180-38FC5B75-CCA2-4F50-898C-6FAEE4A8C3DA

P5875

Q27026180-CE033BFF-6EA7-4011-87BF-3C4C46CDA08A

P698

Q27026180-08AA8EE7-84AB-4274-929A-B768B7D5735A

P921

Q27026180-32B1918C-1A3F-4188-83DE-98E92D1B78E5

P932

Q27026180-1155D44E-D396-4D99-AD7F-81A632D78E2A

P356

P1433

World journal of clinical oncology

P1476

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

@en

P2093

Dimitrios Mantas

http://www.w3.org/2001/XMLSchema#string

Stylianos Kykalos

http://www.w3.org/2001/XMLSchema#string

P2860

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.

Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.

Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment.

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

P304

374-381

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5306/WJCO.V5.I3.374

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Christos Markopoulos

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264711709

http://www.w3.org/2001/XMLSchema#string

P698

25114852

http://www.w3.org/2001/XMLSchema#string

P921

P932

4127608

http://www.w3.org/2001/XMLSchema#string